Exclusive Summary

• - Core patents have expired in major markets, with wide generic entry, enabling fast distribution-led launches.
• - Targets the large segment of 1.28 billion hypertensive patients who need combination therapy, with SPC improving adherence and goal attainment.
• - Aligns with major guidelines advocating early combination; ARB+thiazide is a common first-line option, and the two strengths cover most prescribing needs.
• - China VBP enables low unit cost and reliable capacity, creating strong price advantages versus brands and high-price markets.
• - Quality, stability, and compliance (BE/CTD, nitrosamine control) provide differentiation for mid-to-high tier market access and tenders.